NASDAQ:BLUE - bluebird bio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $146.22 -0.42 (-0.29 %) (As of 03/25/2019 04:00 PM ET)Previous Close$146.64Today's Range$143.5820 - $149.4952-Week Range$87.49 - $199.70Volume507,425 shsAverage Volume555,327 shsMarket Capitalization$8.03 billionP/E Ratio-13.69Dividend YieldN/ABeta2.64 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; and TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts. Receive BLUE News and Ratings via Email Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLUE Previous Symbol CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone339-499-9300Debt Debt-to-Equity RatioN/A Current Ratio9.69 Quick Ratio9.69Price-To-Earnings Trailing P/E Ratio-13.69 Forward P/E Ratio-12.38 P/E GrowthN/A Sales & Book Value Annual Sales$54.58 million Price / Sales147.21 Cash FlowN/A Price / Cash FlowN/A Book Value$34.47 per share Price / Book4.24Profitability EPS (Most Recent Fiscal Year)($10.68) Net Income$-555,630,000.00 Net Margins-1,018.02% Return on Equity-32.15% Return on Assets-27.03%Miscellaneous Employees764 Outstanding Shares54,951,000Market Cap$8.03 billion Next Earnings Date5/1/2019 (Estimated) OptionableOptionable bluebird bio (NASDAQ:BLUE) Frequently Asked Questions What is bluebird bio's stock symbol? bluebird bio trades on the NASDAQ under the ticker symbol "BLUE." How were bluebird bio's earnings last quarter? bluebird bio Inc (NASDAQ:BLUE) issued its earnings results on Thursday, February, 21st. The biotechnology company reported ($2.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.83) by $0.11. The biotechnology company earned $19.20 million during the quarter, compared to the consensus estimate of $9.06 million. bluebird bio had a negative return on equity of 32.15% and a negative net margin of 1,018.02%. The company's revenue for the quarter was up 357.1% on a year-over-year basis. During the same period in the prior year, the business posted ($2.52) EPS. View bluebird bio's Earnings History. When is bluebird bio's next earnings date? bluebird bio is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for bluebird bio. What price target have analysts set for BLUE? 22 analysts have issued twelve-month price targets for bluebird bio's shares. Their predictions range from $120.00 to $239.00. On average, they anticipate bluebird bio's share price to reach $170.2607 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View Analyst Price Targets for bluebird bio. What is the consensus analysts' recommendation for bluebird bio? 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 8 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for bluebird bio. What are Wall Street analysts saying about bluebird bio stock? Here are some recent quotes from research analysts about bluebird bio stock: 1. According to Zacks Investment Research, "bluebird is highly dependent on Celgene for the development of its candidates. Termination of the agreement with Celgene will have a negative impact on the company's growth prospects. While the market for gene therapies promises potential, competition is stiffening in this space. Hence, we expect investors to focus on pipeline updates. The company does not have any approved products in its portfolio yet and an unfavorable outcome from any of the ongoing studies will be a huge setback. Shares have underperformed the industry in the last twelve months. Loss estimates have widened ahead of the Q4 results. Nevertheless, bluebird’s progress with its pipeline is encouraging. bluebird has an impressive pipeline of gene therapies for genetic diseases and cancer. LentiGlobin promises potential. The company’s collaboration with Regeneron is encouraging as it also provides the company with funds." (2/11/2019) 2. Cantor Fitzgerald analysts commented, "We rate bluebird bio Neutral. BLUE, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for rare severe genetic diseases. Its product candidates include Lenti-D, which is in a pivotal clinical study for the treatment of cerebral adrenoleukodystrophy; LentiGlobin, which is in Phase 1/2 clinical studies for the treatment of beta thalassemia major and severe sickle cell disease (SCD); and bb2121 and bb21217 CAR-T, candidates in multiple myeloma. Valuation Summary We value bluebird bio based on a risk-adjusted NPV calculation of its clinical pipeline." (12/3/2018) 3. Maxim Group analysts commented, "bluebird announced new data from its early- and late-stage programs will be presented at this year’s American Society of Hematology (ASH) meeting; gene therapy and CAR-T." (11/1/2018) Has bluebird bio been receiving favorable news coverage? Media coverage about BLUE stock has been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. bluebird bio earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. Who are some of bluebird bio's key competitors? Some companies that are related to bluebird bio include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI) and Regenxbio (RGNX). What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Celgene (CELG), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Netflix (NFLX), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Biogen (BIIB) and Amgen (AMGN). Who are bluebird bio's key executives? bluebird bio's management team includes the folowing people: Mr. Nick Leschly, Pres, CEO & Director (Age 46)Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 46)Dr. Philip D. Gregory, Chief Scientific Officer (Age 48)Mr. Jeffrey T. Walsh, Chief Strategy Officer (Age 53)Dr. David M. Davidson, Chief Medical Officer (Age 55) Who are bluebird bio's major shareholders? bluebird bio's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Baillie Gifford & Co. (8.28%), BlackRock Inc. (5.46%), First Trust Advisors LP (1.37%), Geode Capital Management LLC (1.01%) and Geode Capital Management LLC (1.01%). Company insiders that own bluebird bio stock include Alison Cecily Finger, Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio. Which major investors are selling bluebird bio stock? BLUE stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Jennison Associates LLC, Baillie Gifford & Co., Orbimed Advisors LLC, Tocqueville Asset Management L.P., Los Angeles Capital Management & Equity Research Inc., GAM Holding AG and WS Management Lllp. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Insider Buying and Selling for bluebird bio. Which major investors are buying bluebird bio stock? BLUE stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Fiera Capital Corp, Two Sigma Investments LP, First Trust Advisors LP, American Century Companies Inc., Rhenman & Partners Asset Management AB, FMR LLC and Frontier Capital Management Co. LLC. View Insider Buying and Selling for bluebird bio. How do I buy shares of bluebird bio? Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is bluebird bio's stock price today? One share of BLUE stock can currently be purchased for approximately $146.22. How big of a company is bluebird bio? bluebird bio has a market capitalization of $8.03 billion and generates $54.58 million in revenue each year. The biotechnology company earns $-555,630,000.00 in net income (profit) each year or ($10.68) on an earnings per share basis. bluebird bio employs 764 workers across the globe. What is bluebird bio's official website? The official website for bluebird bio is http://www.bluebirdbio.com. How can I contact bluebird bio? bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected] MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 805 (Vote Outperform)Underperform Votes: 460 (Vote Underperform)Total Votes: 1,265MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: Day Trading - Risk Worth the Reward?